AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $144 | +16.1% | 9,500 | +115.9% | 0.02% | -11.8% |
| Q2 2023 | $124 | +22.8% | 4,400 | 0.0% | 0.02% | +70.0% |
| Q1 2023 | $101 | -41.3% | 4,400 | -58.1% | 0.01% | -33.3% |
| Q4 2022 | $172 | -99.9% | 10,500 | -36.4% | 0.02% | +36.4% |
| Q3 2022 | $156,000 | +38.1% | 16,500 | +35.2% | 0.01% | +57.1% |
| Q2 2022 | $113,000 | -11.0% | 12,200 | +155.7% | 0.01% | 0.0% |
| Q1 2022 | $127,000 | -22.1% | 4,772 | -4.0% | 0.01% | 0.0% |
| Q4 2021 | $163,000 | -28.8% | 4,972 | 0.0% | 0.01% | -30.0% |
| Q3 2021 | $229,000 | -16.4% | 4,972 | 0.0% | 0.01% | -23.1% |
| Q2 2021 | $274,000 | +1041.7% | 4,972 | -51.3% | 0.01% | +1200.0% |
| Q1 2021 | $24,000 | -91.8% | 10,200 | +5.2% | 0.00% | -92.9% |
| Q4 2020 | $294,000 | +23.5% | 9,700 | +42.6% | 0.01% | -6.7% |
| Q3 2020 | $238,000 | -34.4% | 6,800 | 0.0% | 0.02% | -37.5% |
| Q2 2020 | $363,000 | +62.8% | 6,800 | -61.1% | 0.02% | +100.0% |
| Q1 2020 | $223,000 | -34.6% | 17,500 | +136.5% | 0.01% | -42.9% |
| Q4 2019 | $341,000 | +40.9% | 7,400 | -1.0% | 0.02% | -4.5% |
| Q3 2019 | $242,000 | -34.9% | 7,471 | 0.0% | 0.02% | -37.1% |
| Q2 2019 | $372,000 | -6.8% | 7,471 | +26.1% | 0.04% | -14.6% |
| Q1 2019 | $399,000 | -18.1% | 5,925 | -76.7% | 0.04% | -12.8% |
| Q4 2018 | $487,000 | +23.9% | 25,425 | +398.5% | 0.05% | +74.1% |
| Q3 2018 | $393,000 | -43.9% | 5,100 | -63.3% | 0.03% | -51.8% |
| Q2 2018 | $701,000 | +537.3% | 13,900 | +95.6% | 0.06% | +460.0% |
| Q1 2018 | $110,000 | +83.3% | 7,108 | +47.8% | 0.01% | +400.0% |
| Q4 2017 | $60,000 | -88.5% | 4,808 | -84.9% | 0.00% | -90.0% |
| Q3 2017 | $524,000 | +58.8% | 31,892 | -13.4% | 0.02% | +81.8% |
| Q2 2017 | $330,000 | -17.9% | 36,848 | -34.9% | 0.01% | -35.3% |
| Q1 2017 | $402,000 | -30.9% | 56,577 | -28.5% | 0.02% | -19.0% |
| Q4 2016 | $582,000 | -60.9% | 79,157 | -37.2% | 0.02% | -68.7% |
| Q3 2016 | $1,489,000 | +13.1% | 126,026 | +42.7% | 0.07% | 0.0% |
| Q2 2016 | $1,316,000 | +164.3% | 88,296 | +232.7% | 0.07% | +103.0% |
| Q1 2016 | $498,000 | -45.2% | 26,538 | -33.4% | 0.03% | -35.3% |
| Q4 2015 | $908,000 | – | 39,838 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |